Brief: Olix Pharmaceuticals Announces Results From Phase 2A Trial Of OLX10010

OliX Pharmaceuticals

28/04/2023 14:21

April 28 (Reuters) - OliX Pharmaceuticals Inc
 226950.KQ :
    * OLIX PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM A
PHASE 2A
TRIAL OF OLX10010 FOR HYPERTROPHIC SCAR TREATMENT
    * OLIX PHARMACEUTICALS INC - TRIAL CONFIRMS SAFETY AND
TOLERABILITY OF OLX10010 AT BOTH DOSE LEVELS
    * OLIX PHARMACEUTICALS INC - NO NEGATIVE EFFECTS ON
WOUND-HEALING
AFTER SURGERY WERE OBSERVED
    * OLIX PHARMACEUTICALS INC - NO SAFETY ISSUES IDENTIFIED
    * OLIX PHARMACEUTICALS INC - WAS NO CLEAR EVIDENCE FOR
DOSE-DEPENDENT (2MG AND 5MG) EFFECTS

Source text for Eikon:  ID:nBw97v3Gca 
Further company coverage:  226950.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))